Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

The US Department of Health and Human Services' Biomedical Advanced Research Development Authority (BARDA) this week issued a solicitation for proposals for the research and development of immune assays to evaluate responses to COVID-19 vaccines.

Evident Corporation announced that it has been acquired by private equity firm Bain Capital Private Equity from Olympus Corporation pursuant to the definitive agreement signed on August 29, 2022.

In the afternoon of March 30, the first batch of hospitals of the International Hospital Accreditation and Certification Standards (China) accreditation and certification kick-off meeting was held in Qianhai, Shenzhen.

A study of infants in the neonatal intensive care unit in China investigated whether those conceived with assistance had more genetic diagnoses or de novo mutations.

The Berlin, Germany-based firm developed an assay for Marburg virus on its Minoo portable isothermal molecular diagnostic system.

Chinese immunodiagnostics market has maintained an overall growth rate of approximately 20% over the past five years, and is expected to reach a market size of CNY 52.4 billion in 2022.

Danaher subsidiary Leica Biosystems said Monday that it secured US Food and Drug Administration 510(k) clearance for its Bond MMR Antibody Panel to help identify potential Lynch syndrome in colorectal cancer patients.

Sysmex Europe and Cerca Biotech said Monday that they have inked a deal for Sysmex to distribute Cerca's molecular breast cancer assay in 13 European markets.

Recently, WillingMed Technology(Beijing) Co., Ltd. announced the completion of a CNY hundreds of millions Series B financing round.

Stilla Technologies and Atila BioSystems said on Thursday that they will codevelop digital PCR kits for cancer liquid biopsy applications.